Literature DB >> 21217778

A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors.

J S W Low1, Q Tao, K M Ng, H K Goh, X-S Shu, W L Woo, R F Ambinder, G Srivastava, M Shamay, A T C Chan, N C Popescu, W-S Hsieh.   

Abstract

The critical 8p22 tumor suppressor deleted in liver cancer 1 (DLC1) is frequently inactivated by aberrant CpG methylation and/or genetic deletion and implicated in tumorigeneses of multiple tumor types. Here, we report the identification and characterization of its new isoform, DLC1 isoform 4 (DLC1-i4). This novel isoform encodes an 1125-aa (amino acid) protein with distinct N-terminus as compared with other known DLC1 isoforms. Similar to other isoforms, DLC1-i4 is expressed ubiquitously in normal tissues and immortalized normal epithelial cells, suggesting a role as a major DLC1 transcript. However, differential expression of the four DLC1 isoforms is found in tumor cell lines: Isoform 1 (longest) and 3 (short thus probably nonfunctional) share a promoter and are silenced in almost all cancer and immortalized cell lines, whereas isoform 2 and 4 utilize different promoters and are frequently downregulated. DLC1-i4 is significantly downregulated in multiple carcinoma cell lines, including 2/4 nasopharyngeal, 8/16 (50%) esophageal, 4/16 (25%) gastric, 6/9 (67%) breast, 3/4 colorectal, 4/4 cervical and 2/8(25%) lung carcinoma cell lines. The functional DLC1-i4 promoter is within a CpG island and is activated by wild-type p53. CpG methylation of the DLC1-i4 promoter is associated with its silencing in tumor cells and was detected in 38-100% of multiple primary tumors. Treatment with 5-aza-2'-deoxycytidine or genetic double knockout of DNMT1 and DNMT3B led to demethylation of the promoter and reactivation of its expression, indicating a predominantly epigenetic mechanism of silencing. Ectopic expression of DLC1-i4 in silenced tumor cells strongly inhibited their growth and colony formation. Thus, we identified a new isoform of DLC1 with tumor suppressive function. The differential expression of various DLC1 isoforms suggests interplay in modulating the complex activities of DLC1 during carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217778      PMCID: PMC3385516          DOI: 10.1038/onc.2010.576

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

Review 1.  Rho GTPase-activating proteins in cell regulation.

Authors:  Sun Young Moon; Yi Zheng
Journal:  Trends Cell Biol       Date:  2003-01       Impact factor: 20.808

2.  Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes.

Authors:  Sai Wah Tsao; Xianghong Wang; Yu Liu; Yuk Chun Cheung; Huichen Feng; Zhong Zheng; Natalie Wong; P W Yuen; Angela K F Lo; Y C Wong; D P Huang
Journal:  Biochim Biophys Acta       Date:  2002-06-12

Review 3.  Rescuing the function of mutant p53.

Authors:  A N Bullock; A R Fersht
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

Review 4.  Two genetic hits (more or less) to cancer.

Authors:  A G Knudson
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

5.  DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.

Authors:  I O Ng; Z D Liang; L Cao; T K Lee
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

6.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.

Authors:  Ina Rhee; Kurtis E Bachman; Ben Ho Park; Kam-Wing Jair; Ray-Whay Chiu Yen; Kornel E Schuebel; Hengmi Cui; Andrew P Feinberg; Christoph Lengauer; Kenneth W Kinzler; Stephen B Baylin; Bert Vogelstein
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

7.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22.

Authors:  Daiya Takai; Peter A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

8.  Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.

Authors:  Yick-Pang Ching; Chun-Ming Wong; Shing-Fai Chan; Thomas Ho-Yin Leung; David Chi-Heng Ng; Dong-Yan Jin; Irene Oi-lin Ng
Journal:  J Biol Chem       Date:  2003-01-16       Impact factor: 5.157

9.  Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform.

Authors:  Mohammad G Sabbir; Nichola Wigle; Shauna Loewen; Yuan Gu; Cordula Buse; Geoffrey G Hicks; Michael R A Mowat
Journal:  BMC Biol       Date:  2010-03-03       Impact factor: 7.431

10.  Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells.

Authors:  Qian Tao; He Huang; Theresa M Geiman; Chai Yen Lim; Li Fu; Guo-Hua Qiu; Keith D Robertson
Journal:  Hum Mol Genet       Date:  2002-09-01       Impact factor: 6.150

View more
  29 in total

Review 1.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

Review 2.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

3.  DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.

Authors:  Rakesh Joshi; Lyugao Qin; Xuan Cao; Shanshan Zhong; Courtney Voss; Weiping Min; Shawn S C Li
Journal:  J Biol Chem       Date:  2019-12-05       Impact factor: 5.157

4.  Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter.

Authors:  Yufei Liu; Jun Zhou; Yuchang Hu; Junjie Wang; Chengfu Yuan
Journal:  Mol Cell Biochem       Date:  2016-11-10       Impact factor: 3.396

Review 5.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

6.  Patterns of somatic uniparental disomy identify novel tumor suppressor genes in colorectal cancer.

Authors:  Keyvan Torabi; Rosa Miró; Nora Fernández-Jiménez; Isabel Quintanilla; Laia Ramos; Esther Prat; Javier del Rey; Núria Pujol; J Keith Killian; Paul S Meltzer; Pedro Luis Fernández; Thomas Ried; Juan José Lozano; Jordi Camps; Immaculada Ponsa
Journal:  Carcinogenesis       Date:  2015-08-04       Impact factor: 4.944

7.  Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3'-Untranslated Region of DLC1.

Authors:  Sheril June Ankasha; Mohamad Nasir Shafiee; Norhazlina Abdul Wahab; Raja Affendi Raja Ali; Norfilza Mohd Mokhtar
Journal:  Int J Environ Res Public Health       Date:  2021-05-27       Impact factor: 3.390

8.  The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.

Authors:  Mohammad Golam Sabbir; Heather Prieditis; Esther Ravinsky; Michael R A Mowat
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

Review 9.  Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).

Authors:  Drazen B Zimonjic; Nicholas C Popescu
Journal:  Int J Oncol       Date:  2012-05-10       Impact factor: 5.650

10.  Caveolin-1 protects B6129 mice against Helicobacter pylori gastritis.

Authors:  Ivana Hitkova; Gang Yuan; Florian Anderl; Markus Gerhard; Thomas Kirchner; Simone Reu; Christoph Röcken; Claus Schäfer; Roland M Schmid; Roger Vogelmann; Matthias P A Ebert; Elke Burgermeister
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.